| ORIGINAL ARTICLE |
|
| Year : 2015 | Volume
: 21
| Issue : 3 | Page : 175-180 |
|
|
Doxorubicin-loaded drug-eluting beads versus conventional transarterial chemoembolization for nonresectable hepatocellular carcinoma
Mohammad Arabi1, Ali BenMousa2, Khaled Bzeizi2, Fares Garad1, Ishtiaq Ahmed1, Melfi Al-Otaibi2
1 Department of Medical Imaging, Division of Interventional Radiology, Prince Sultan Military Medical City (PSMMC), Riyadh, Saudi Arabia
2 Department of Hepatology, Prince Sultan Military Medical City (PSMMC), Riyadh, Saudi Arabia
Correspondence Address:
Mohammad Arabi
Consultant Interventional Radiologist, Department of Medical Imaging, Prince Sultan Military Medical City, Riyadh, 11159
Saudi Arabia
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/1319-3767.157571
|
|
|
Background/Aims: To compare the efficacy and safety profile of doxorubicin-loaded drug-eluting beads (DEB) to the conventional TACE (C-TACE) in the management of nonresectable hepatocellular carcinoma (HCC). Patients and Methods: All patients with nonresectable HCC who underwent either c-TACE or DEB-TACE during the period 2006–2014 and fulfilled the inclusion criteria were included in this retrospective study. Primary endpoints were tumor response rate at first imaging follow up, treatment-related liver toxicity, and treatment emergent adverse events (TEAE). Results: Thirty-five patients (51 procedures) in the DEB-TACE group and 19 patients (25 procedures) in the c-TACE group were included in the analysis. The median follow up time was 61 days (range 24– 538 days) in the DEB-TACE group and 86 days (range 3– 152 days) for the c-TACE group patients. Complete response (CR), objective response (OR), disease control (DC), and progressive disease (PD) rates were 11%, 24%, 17%, and 47%, respectively, in the DEB = TACE group compared with 4%, 32%, 28%, and 36%, respectively, in the c-TACE group. Mean ALT change from baseline was minimal in the DEB-TACE patients compared with c-TACE group (7.2 vs 79.4 units, P = 0.001). Hospital stay was significantly shorter in the DEB-TACE group (7.8 days vs 11.4 days; P = 0.038). The 2-year survival rate was 60% for the c-TACE patients and 58% for the DEB-TACE (P = 0.4). Conclusions: DEB-TACE compared with c-TACE is associated with lesser liver toxicity benefit, better tolerance, and shorter hospital stay. The two modalities however had similar survival and efficacy benefits. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
Next article
